Establishment Labs (ESTA) Q4 2025 earnings summary
Event summary combining transcript, slides, and related documents.
Q4 2025 earnings summary
8 Jul, 2026Executive summary
Q4 2025 revenue reached $64.6 million, up 45.2% year-over-year, with US Motiva revenue at $17.3 million and total 2025 revenue at $211.1 million, a 27.2% increase over 2024.
Operational leverage improved, with gross margin exceeding 70% for the second consecutive quarter and adjusted EBITDA turning positive at $5.5 million in Q4.
Net loss from operations in Q4 was $3.9 million, down 79% from Q4 2024, and full-year net loss was $51.1 million, improved from $84.6 million in 2024.
Cash balance at year-end 2025 was $75.6 million, up $4.9 million sequentially from Q3.
Management transition announced: Raj Denhoy to SVP, Global Strategy, and Cassandra Harris as CFO.
Financial highlights
Q4 2025 gross profit was $45.5 million, or 70.5% of revenue, up 200 basis points year-over-year.
Adjusted EBITDA for Q4 was $5.5 million, a significant improvement from a loss of $13.1 million in Q4 2024.
SG&A expenses were $44.0 million, flat year-over-year; R&D expenses rose to $5.4 million due to personnel and regulatory costs.
Total operating expenses for Q4 were $49.5 million.
Basic and diluted net loss per share for Q4 was $0.09, improved from $1.19 in Q4 2024.
Outlook and guidance
2026 revenue guidance is $264–$266 million, representing 25%+ growth over 2025.
2027 revenue growth is projected to be at least 25%.
First positive cash flow quarter expected in 2026, with full-year positive cash flow anticipated in 2027.
Gross margins projected to increase by 200–300 basis points in 2026.
Free cash use in 2026 expected to be less than half of 2025, with no need for additional capital.
Latest events from Establishment Labs
- 2025 guidance targets $205–$210M revenue, EBITDA positive, and rapid US-driven growth.ESTA
Investor Day 20259 Jul 2026 - Rapid U.S. growth, premium pricing, and innovation set the stage for market dominance and expansion.ESTA
TD Cowen 46th Annual Health Care Conference8 Jul 2026 - All proposals passed with majority approval and no shareholder questions were raised.ESTA
AGM 202628 May 2026 - Q1 revenue up 45% year-over-year, gross margin at 70.7%, and 2026 guidance raised.ESTA
Q1 20268 May 2026 - Director compensation figures were corrected, and additional equity awards disclosed for consulting roles.ESTA
Proxy filing24 Apr 2026 - Virtual meeting to elect directors, approve pay, and ratify auditor, with strong governance focus.ESTA
Proxy filing10 Apr 2026 - Vote on directors, executive pay, and auditor ratification at the May 2026 annual meeting.ESTA
Proxy filing10 Apr 2026 - Q2 revenue rose 18.7% sequentially; FDA approval for Motiva Implants expected soon.ESTA
Q2 20242 Feb 2026 - Innovation, global expansion, and regulatory progress position the company for rapid growth.ESTA
Goldman Sachs 45th Annual Global Healthcare Conference1 Feb 2026